ACRP-CP Certified Professional

According to ICH E6(R3), what is the primary objective of the Good Clinical Practice (GCP) guideline?

• ATo provide a unified standard that facilitates mutual acceptance of clinical data by regu…
• BTo establish financial guidelines for clinical trial funding
• CTo define the organizational structure of pharmaceutical companies
• DTo regulate the pricing of investigational products

Which of the following is a fundamental principle of ICH GCP regarding the rights of trial subjects?

• ATrial subjects may be compensated only after completing the full study
• BThe rights, safety, and well-being of trial subjects are the most important consideration…
• CSubject rights are secondary to scientific advancement in Phase I trials
• DTrial subjects have no right to withdraw once they have signed the informed consent form

According to ICH GCP, which document should be reviewed by the investigator before initiating a clinical trial?

• AThe marketing authorization application
• BThe Investigator's Brochure (IB)
• CThe annual financial report of the sponsor
• DThe manufacturing license for the investigational product

A clinical research coordinator discovers that a study subject received a dose of the investigational product that was 50% higher than specified in the protocol. What is the FIRST action the coordinator should take?

• ADiscontinue the subject from the study immediately
• BWait for the next scheduled visit to address the issue
• CEnsure the subject's immediate safety and document the event as a protocol deviation
• DContact the sponsor to request additional investigational product

Which of the following is considered an essential document that should be maintained in the trial master file according to ICH GCP?

• AInvestigator's personal financial portfolio
• BSigned informed consent forms for each subject
• CThe sponsor's corporate organizational chart
• DMarketing materials for the investigational product

During a monitoring visit, a CRA discovers that the investigator has not been reporting adverse events within the timeframes specified in the protocol. What should the CRA do?

• AIgnore the issue since the events were eventually reported
• BDocument the finding, ensure corrective actions are implemented, and report to the sponsor
• CImmediately close the site without further discussion
• DInstruct the site staff to backdate the adverse event reports

According to ICH GCP, what is the primary purpose of source document verification (SDV) during monitoring?

• ATo verify that the data reported in the CRFs are accurate and consistent with the source…
• BTo ensure the site has enough office supplies
• CTo assess the investigator's financial status
• DTo evaluate the aesthetic quality of the facility

Which of the following best describes the role of a quality management system (QMS) in clinical trials as outlined in ICH E6(R3)?

• AA system focused solely on reducing trial costs
• BA systematic approach to ensure trial quality, including risk identification, assessment,…
• CA database for storing subject demographic information
• DA training program exclusively for new clinical research staff

A sponsor implements risk-based monitoring (RBM) for a multi-site clinical trial. Which of the following activities is MOST consistent with an RBM approach?

• APerforming 100% SDV at every site regardless of risk assessment
• BEliminating all on-site monitoring visits
• CUsing centralized data analytics to identify sites with data anomalies and prioritizing o…
• DDelegating all monitoring responsibilities to the investigator

According to ICH GCP, which of the following must be included in the trial protocol?

• AThe investigator's vacation schedule
• BA description of the statistical methods to be employed, including the planned number of…
• CThe sponsor's marketing strategy for the product
• DThe salary structure for site staff

A clinical trial has three protocol amendments within six months. Which of the following is the MOST appropriate action?

• AContinue without concern since amendments are a normal part of trial conduct
• BReview the root causes of the amendments and assess whether the original protocol design…
• CTerminate the trial immediately due to excessive amendments
• DRemove the principal investigator from the study

Which of the following statements about the sponsor's responsibilities is correct according to ICH GCP?

• AThe sponsor may transfer any or all trial-related duties to a CRO but retains ultimate re…
• BOnce a CRO is engaged, the sponsor has no further responsibility for the trial
• CThe sponsor is only responsible for financing the trial
• DThe sponsor's responsibilities end once the investigational product is delivered to the s…

During a pre-study visit, which of the following is the MOST important factor for the monitor to assess?

• AThe color scheme of the clinic waiting room
• BWhether the site has adequate resources, facilities, and qualified staff to conduct the t…
• CThe investigator's personal hobbies
• DThe site's social media presence

A site is conducting a clinical trial and the IRB/IEC approval is about to expire. What is the required action according to GCP?

• AContinue enrolling subjects while the renewal is being processed
• BSubmit a continuing review application to the IRB/IEC before the approval expires to main…
• CClose the site permanently since the approval has lapsed
• DTransfer all subjects to another site without notification

Which of the following BEST describes the concept of 'audit trail' in clinical trials?

• AA walking path used for facility inspections
• BA chronological record that permits reconstruction of the course of events relating to th…
• CA financial ledger tracking trial expenses
• DA list of all monitors who visited the site

A sponsor discovers during centralized monitoring that one site has significantly lower adverse event reporting rates compared to similar sites. What is the MOST appropriate response?

• ACommend the site for having fewer adverse events
• BConduct a targeted on-site visit to investigate potential underreporting of adverse events
• CReduce the monitoring frequency since the site appears to have fewer issues
• DImmediately report the site to regulatory authorities without further investigation

According to ICH GCP, what is the investigator's responsibility regarding the delegation of trial-related duties?

• AThe investigator may delegate duties to anyone without documentation
• BThe investigator should ensure a record is kept of the persons to whom trial-related acti…
• CThe investigator cannot delegate any duties under any circumstances
• DDelegation of duties transfers all legal responsibility to the delegated individual

Which of the following scenarios represents a critical finding during a GCP audit?

• AMinor typographical errors in source documents
• BA subject was enrolled without obtaining informed consent prior to any trial-related proc…
• CA CRF was submitted one day late
• DThe site filing system uses a different color-coding scheme than recommended

In a multicenter clinical trial, the coordinating investigator's primary responsibility includes which of the following?

• AManaging the financial budgets of all participating sites
• BCoordinating the conduct of the trial among multiple investigators and sites
• CPersonally performing all procedures at every participating site
• DHiring and firing staff at all participating sites

A clinical trial site receives a regulatory authority inspection notice. According to ICH GCP, the investigator must:

• ARefuse the inspection and contact a lawyer
• BPermit the sponsor and the regulatory authority access to all trial-related records
• CDestroy all trial documents before the inspection
• DOnly allow access to favorable trial results

Which of the following best describes the 'risk-proportionate approach' that ICH E6(R3) makes a core principle?

• AAll trials should have the same level of monitoring regardless of complexity
• BThe extent of monitoring and overall quality management activities should be proportionat…
• COnly high-risk trials require any form of monitoring
• DRisk assessment should only be performed at the end of the trial

According to ICH GCP, a monitor documents monitoring activities in reports to the sponsor. Which of the following should these reports include?

• AOnly positive findings from the visit
• BA summary of what was reviewed, significant findings and conclusions, and the actions req…
• COnly financial information discussed during the visit
• DA summary of the monitor's travel expenses

In a clinical trial, which of the following is the MOST significant consequence of failing to maintain an adequate audit trail for electronic data?

• AThe trial may need to use more paper forms
• BThe integrity and reliability of the trial data may be questioned, potentially invalidati…
• CThe site will receive a bonus for efficiency
• DThe trial timeline will be shortened